

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Link-Asia International MedTech Group Limited

環亞國際醫療科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR (2) CHANGE OF COMPOSITION OF BOARD COMMITTEES AND (3) COMPLIANCE WITH THE LISTING RULES

The Board is pleased to announce that Mr. Wu Chi King (“**Mr. Wu**”) has been appointed as an Independent Non-executive Director, the member of Audit Committee (the “**Audit Committee**”), the Chairman of Remuneration Committee (the “**Remuneration Committee**”) and the member of Nomination Committee (the “**Nomination Committee**”) of the Company with effect from 6 September 2023. Following the appointment of Mr. Wu, the Company is in compliance with the requirement under Rule 3.10 (1) of the Listing Rules.

(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Link-Asia International MedTech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Wu Chi King (“**Mr. Wu**”) has been appointed as an Independent Non-executive Director of the Company (the “**Appointment**”) with effect from 6 September 2023. Set out below are the personal details of Mr. Wu:

Mr. Wu Chi King (“**Mr. Wu**”), aged 41, received a Bachelor of Computer Science from Monash University and is a Certified Practising Accountant (CPA) of Certified Practising Accountant Australia. He has accumulated extensive experience in finance and accounting by working in various listed and sizable companies in Hong Kong. Mr. Wu is currently the financial controller of Hang Heung Cake Shop Company Limited, a private company incorporated in Hong Kong with limited liability which is a food product manufacturer. Mr. Wu is also an independent non-executive director of (i) Palinda Group Holdings Limited, a company whose shares are listed on GEM of the Stock Exchange (Stock Code: 8179) since September 2022; (ii) Mansion International Holdings Limited, a company whose shares are listed on GEM of the Stock Exchange

(Stock Code: 8456) since June 2021; and (iii) Wan Cheng Metal Packaging Company Limited, a company whose shares are listed on GEM of the Stock Exchange (Stock Code: 8291) since June 2020.

Mr. Wu will enter into an appointment letter as an independent non-executive Director with the Company for an initial term of three years, and will be subject to retirement by rotation and re-election at general meeting of the Company in accordance with the Company's articles of association. Mr. Wu is entitled to a directors' fee of HK\$240,000 per annum as specified in his letter of appointment, which is determined by the Board (the decision of which was based on the recommendation of the Remuneration Committee of the Company) with reference to his duties and responsibilities in the Company, the prevailing market rate and the remuneration policy of the Company. Such remuneration is subject to review by the Remuneration Committee and the Board from time to time.

Save as disclosed above, as at the date of this announcement, Mr. Wu: (i) does not hold any other positions with the Company or other members of the Group; (ii) does not have any relationships with any directors, senior management or substantial or controlling shareholders (as respectively defined in the Listing Rules) of the Company; (iii) has not at any time during the three years preceding the date of this announcement served nor is currently serving as a director of any other publicly listed companies in Hong Kong or overseas; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of Laws of Hong Kong).

Saved as disclosed above, there is no other information to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules (particularly in relation to subparagraphs (h) to (v) therein) nor are there any other matters that need to be brought to the attention of the shareholders of the Company relating to the appointment of Mr. Wu. The Board would like to take this opportunity to welcome Mr. Wu on joining the Board.

(2) CHANGE OF COMPOSITION OF BOARD COMMITTEES

Mr. Wu has been appointed as the member of the Audit Committee, the chairman of the Remuneration Committee and a member of the Nomination Committee with effect from 6 September 2023.

(3) COMPLIANCE WITH THE LISTING RULES

According to Rule 3.10(1) of the Listing Rules, the Company is required to have at least three independent non-executive Directors. According to Rule 3.21 of the Listing Rules, the Audit Committee must comprise a minimum of three members, and comprise non-executive Directors only. Following the appointment of Mr. Wu, (i) the Company has three independent non-executive Directors, thus the number of independent non-executive Directors meets the minimum number required under Rule 3.10(1) of the Listing Rules; and (ii) the Audit Committee has three members and all members are non-executive Directors, thus meets the requirement under Rule 3.21 of the Listing Rules.

On behalf of the Board
Link-Asia International MedTech Group Limited
Lin Dailian
Chairman and executive Director

Hong Kong, 6 September 2023

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Liu Zhiwei, Ms. Lin Xiaoshan and Ms. Bian Sulan as executive Directors; Mr. Li Huiwu, Mr. Wu Chi King and Mr. Chak Chi Shing as independent non-executive Directors.